(NYSE: TMO) Thermo Fisher Scientific's forecast annual revenue growth rate of 5.84% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.19%.
Thermo Fisher Scientific's revenue in 2026 is $44,556,000,000.On average, 29 Wall Street analysts forecast TMO's revenue for 2026 to be $17,580,491,847,300, with the lowest TMO revenue forecast at $16,771,399,163,868, and the highest TMO revenue forecast at $18,603,930,939,520. On average, 29 Wall Street analysts forecast TMO's revenue for 2027 to be $18,478,369,265,048, with the lowest TMO revenue forecast at $17,629,156,283,264, and the highest TMO revenue forecast at $19,900,782,435,324.
In 2028, TMO is forecast to generate $19,706,124,691,468 in revenue, with the lowest revenue forecast at $18,677,484,819,832 and the highest revenue forecast at $21,572,833,017,568.